BALCHEM CORP — Form 8-K
Filed July 31, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 47/100
What the filing says
Balchem reported Q2 2026 net sales of $284.0M (+11.2% YoY), net earnings $44.6M (+16.6%), and adjusted EBITDA $77.9M (+12.6%). On July 24, 2026, the company amended its revolving credit facility, increasing borrowing capacity from $550M to $650M with maturity extended from July 27, 2027 to July 24, 2031. All three segments (Human Nutrition & Health, Animal Nutrition & Health, Specialty Products) delivered record or strong quarterly results. The company repurchased $29M of stock in Q2 and $114M over trailing twelve months. Leverage ratio remains conservative at 0.3x net debt/TTM adjusted EBITDA.
Why this rating
Strong operational performance across all segments with 11%+ sales growth and improved profitability. Credit facility expansion provides $100M additional capacity and 4-year maturity extension, enabling M&A and strategic flexibility. However, relative to $5.1B market cap, $284M quarterly sales and $100M credit increase represent solid but incremental progress, not transformational. No major acquisition announced. Share repurchases and dividend sustainability are positive but routine capital allocation.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.